Samsung Biologics revenue and financials
₩1,277,000.00Change from previous close: −2.52%Absolute change: −₩33,000.00
In the fiscal year ended December 2025, Samsung Biologics reported revenue of ₩4.56T (+30.31% year over year). Net income was ₩1.78T, a net margin of 39.2%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +30.31%
- 2025 vs 2024
- Net income growth
- +64.71%
- 2025 vs 2024
- Net margin
- 39.2%
- 2024: 31.0%
Financial data
Amounts in millions of KRW; per-share values in KRW; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 11,060,742 | 17,336,296 | 16,046,197 | 16,582,050 | 7,970,011 |
| Current assets | 4,408,367 | 5,518,118 | 5,521,988 | 6,457,657 | 2,823,175 |
| Cash and equivalents | 148,851 | 391,222 | 367,937 | 890,820 | 47,410 |
| Short-term investments | 1,336,232 | 940,067 | 1,688,338 | 2,204,212 | 473,985 |
| Receivables | 676,467 | -0.0 | — | — | 0.0 |
| Inventory | 2,128,164 | 2,818,276 | 2,641,368 | 2,375,819 | 1,012,871 |
| Net property, plant and equipment | 6,037,532 | 5,837,482 | 4,342,424 | 3,871,452 | 2,227,687 |
| Goodwill | — | 1,677,608 | 1,677,608 | 1,677,608 | — |
| Other intangible assets | 60,193 | 1,294,705 | 1,580,423 | 1,541,850 | 32,172 |
| Long-term investments | 78,325 | 59,605 | 47,435 | 38,110 | 2,661,499 |
| Current liabilities | 2,532,917 | 3,853,188 | 4,157,861 | 4,181,542 | 1,107,295 |
| Accounts payable | 59,814 | 177,992 | 201,709 | 59,616 | 32,251 |
| Long-term debt | 599,012 | 1,012,757 | 239,783 | 965,090 | 1,114,684 |
| Total debt | 927,094 | 1,486,239 | 1,909,333 | 2,514,033 | — |
| Total liabilities | 3,609,631 | 6,431,620 | 6,215,705 | 7,597,576 | 2,978,909 |
| Total equity (incl. minority) | 7,451,111 | 10,904,676 | 9,830,492 | 8,984,474 | 4,991,102 |
| Retained earnings | 6,870,961 | 5,086,609 | 4,003,293 | 3,145,601 | 2,347,187 |